Journal of microbiology, epidemiology and immunobiologyJournal of microbiology, epidemiology and immunobiology0372-93112686-7613Central Research Institute for Epidemiology110910.36233/0372-9311-159UnknownImmunogenic properties of the preparation containing the Chikungunya virus antigen inactivated by β-propiolactoneIgnatyevG. M.<p>Georgy M. Ignatyev — D. Sci. (Med.), Professor, Deputy Head, Department for quality and innovative development, Chumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences.<br />Moscow.</p>ignatjev_gm@chumakovs.suhttps://orcid.org/0000-0002-9731-3681KaaK. V.<p>Konstantin V. Kaa — junior researcher, Laboratory of molecular biology of viruses, Chumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences.<br />Moscow.</p>fake@neicon.ruhttps://orcid.org/0000-0002-8446-1853AntonovaL. P.<p>Lilia P. Antonova — junior researcher, Laboratory of molecular biology of viruses, Chumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences.<br />Moscow.</p>fake@neicon.ruhttps://orcid.org/0000-0002-1221-1134AtrasheuskayaA. V.<p>Alena V. Atrasheuskaya — senior specialist, R&D Department, Saint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations.<br />Saint Petersburg.</p>fake@neicon.ruhttps://orcid.org/0000-0002-2491-4072IshmukhametovA. A.<p>Aidar A. Ishmukhametov — D. Sci. (Med.), Professor, General Director, Chumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences.<br />Moscow.</p>fake@neicon.ruhttps://orcid.org/0000-0001-6130-4145Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of SciencesSaint-Petersburg Scientific Research Institute of Vaccines and Serums and the Enterprise for the Production of Bacterial Preparations021120219855195270211202102112021Copyright © 2021, Ignatyev G.M., Kaa K.V., Antonova L.P., Atrasheuskaya A.V., Ishmukhametov A.A.2021<p><strong>Introduction</strong>. Cases of Chikungunya fever have been reported in more than 100 countries in Europe, Oceania, Africa, Asia, the Caribbean, and America. The musculoskeletal disorders typical for Chikungunya fever can last from several months to a year and even lead to disability. The infection is believed to provide lifelong immunity. This factor and the lack of specific therapy make vaccination the most promising method for preventing Chikungunya fever.<br /><strong>Materials and methods</strong>. The purified inactivated preparation with the different doses of the CHIKV antigen was injected intramuscularly to BALB/c mice twice with an interval of 14 days. Indicators of humoral and cellular immunity were assessed in dynamics in ELISA, the neutralization test and proliferation test of splenocytes. Results. The purified preparation containing the CHIKV antigen inactivated by beta-propiolactone had pronounced immunogenic properties. The most prominent immune response in ELISA and neutralization test was registered for a dose of 40 g. Stimulation with the specific CHIKV antigen caused a pronounced proliferation of animals' splenocytes. The peak values of specific humoral and cellular immunity parameters were registered 14 days after the second injection.<br /><strong>Discussion</strong>. The purified preparation containing the CHIKV antigen inactivated by beta-propiolactone had demonstrated the sufficient immunogenic properties. The immunizing dose of 40 g CHIKV selected as a result of the studies caused in BALB/c mice the development of the humoral immunity characterized by the specific IgG with neutralizing activity, and the specific cell immunity characterized by the animals' splenocytes proliferation after stimulation with CHIKV antigen.<br /><strong>Conclusion</strong>. The purified -PL inactivated preparation of the CHIKV antigen at a dose of 40 g to demonstrated pronounced immunogenicity in BALB/c mice after two-dose immunization. The developed preparation can be considered as promising for the prevention of Chikungunya fever using the dose and scheme tested in this study.</p>inactivated virus Chikungunya antigenmice BALB/chumoral and cell immunityинактивированный антиген вируса Чикунгуньямыши BALB/cгуморальный и клеточный иммунитет[1. Weaver S.C., Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N. Engl. J. Med. 2015; 372(13): 1231-9. https://doi.org/10.1056/NEJMra1406035][2. Simon F., Javelle E., Cabie A., Bouquillard E., Troisgros O., Gentile G., et al. French guidelines for the management of chikungunya (acute and persistent presentations). Med. Mal. Infec/. 2015; 45(7): 243-63. https://doi.org/10.1016/j.medmal.2015.05.007][3. Schrauf S., Tschismarov R., Tauber E., Ramsauer K. Current efforts in the development of vaccines for the prevention of Zika and Chikungunya infections. Front. Immunol. 2020; (11): 592. https://doi.org/10.3389/fimmu.2020.00592][4. Reyes-Sandoval A. 51 years in of Chikungunya clinical vaccine development: A historical perspective. Hum. Vaccin. Immunother. 2019; 15(10): 2351-8. https://doi.org/10.1080/21645515.2019.1574149][5. Erasmus J.H., Rossi S.L., Weaver S.C. Development of vaccines for Chikungunya fever. J. Inf. Dis. 2016; 214(S5): S488-96. https://doi.org/10.1093/infdis/jiw271][6. Porterfield J.S. Cross-neutralization studies with group A arthropod-borne viruses. Bull. WHO. 1961; 24(6): 735-41.][7. Hearn H.J., Rainey C.T. Cross protection in animals infected with group A arboviruses. J. Immunol. 1963; 90: 720-4.][8. Powers A.M., Brault A.C., Tesh R.B., Weaver S.C. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 2000; 81(Pt. 1): 471-9. https://doi.org/10.1099/0022-1317-81-2-471][9. Galatas B., Ly S., Duong V., Baisley K., Nguon K., Chan S., et al. Long-lasting immune protection and other epidemiological findings after Chikungunya emergence in a Cambodian Rural Community, April (2012). PLoS Negl. Trop. Dis. 2016; 10(1): e0004281. https://doi.org/10.1371/journal.pntd.0004281][10. Pierro A., Rossini G., Gaibani P., Finarelli A.C., Moro M.L., Landini M.P., et al. Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy. New Microbes New Infect. 2015; 7: 23-5. https://doi.org/10.1016/j.nmni.2015.04.002][11. Harrison V.R., Eckels K.H., Bartelloni P.J., Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J. Immunol. 1971; (107): 643-6.][12. Langsjoen R.M., Haller S.L., Roy C.J., Vinet-Oliphant H., Ber-gren N.A., Erasmus J.H., et al. Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models. mBio. 2018; 9(2): e02449-17. https://doi.org/10.1128/mBio.02449-17][13. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine. 2009; 27(18): 2513-22. https://doi.org/10.1016/j.vaccine.2009.02.062][14. Kumar M., Sudeep A.B., Arankalle V.A. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine. 2012; 30(43): 6142-9. https://doi.org/10.1016/j.vaccine.2012.07.072][15. Игнатьев Г.М., Каа К.В., Оксанич А.С., Антонова Л.П., Самарцева Т.Г., Мефед К.М. и др. Индикация и идентификация вирусов денге и Чикунгунья в комарах рода Aedes spp., отловленных в Центральной Америке. Журнал микробиологии, эпидемиологии и иммунобиологии. 2020; 97(3): 227-32. https://doi.org/10.36233/0372-9311-2020-97-3-4][16. Mayer U.B., Haller C., Haidinger W., Atrasheuskaya A., Bukin E., Lubitz W., et al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immun. 2005; (8): 4810-7. https://doi.org/10.1128/IAI.73.8.4810-4817.2005][17. Delrue I., Verzele D., Madder A., Nauwynck J. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert. Rev. Vaccines. 2012; 11(6): 695-719. https://doi.org/10.1586/erv.12.38][18. Davenport B.J., Bullock C., McCarthy M.K., Hawman D.W., Murphy K.M., Kedl R.M., et al. Chikungunya virus evades antiviral CD8T cell responses to establish persistent infection in joint-associated tissues. J. Virol. 2020; (94): e02036-19. https://doi.org/10.1128/JVI.02036-19][19. Uittenbogaard J.P., Zomer B., Hoogerhout P., Metz B. Reactions of в-propiolactone with nucleobase analogues, nucleosides, and peptides. J. Biol. Chem. 2011; 286(42): 36198-214. https://doi.org/10.1074/jbc.M111.279232]